Literature DB >> 28512226

Reply to Padmanabhan and Dixit: Hepatitis C virus entry inhibitors for optimally boosting direct-acting antiviral-based treatments.

Hirofumi Ohashi1,2, Yoshiki Koizumi3, Kento Fukano1,4, Takaji Wakita1, Alan S Perelson5, Shingo Iwami6,7,8, Koichi Watashi9,2,8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28512226      PMCID： PMC5468609          DOI： 10.1073/pnas.1705234114

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  11 in total

Review 1.  Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.

Authors:  Ting-Chao Chou
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

2.  Discovery of chemical inhibitors of the selective transfer of lipids mediated by the HDL receptor SR-BI.

Authors:  Thomas J F Nieland; Marsha Penman; Limor Dori; Monty Krieger; Tomas Kirchhausen
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-18       Impact factor: 11.205

3.  Broadly neutralizing antibodies abrogate established hepatitis C virus infection.

Authors:  Ype P de Jong; Marcus Dorner; Michiel C Mommersteeg; Jing W Xiao; Alejandro B Balazs; Justin B Robbins; Benjamin Y Winer; Sherif Gerges; Kevin Vega; Rachael N Labitt; Bridget M Donovan; Erick Giang; Anuradha Krishnan; Luis Chiriboga; Michael R Charlton; Dennis R Burton; David Baltimore; Mansun Law; Charles M Rice; Alexander Ploss
Journal:  Sci Transl Med       Date:  2014-09-17       Impact factor: 17.956

4.  Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge.

Authors:  Mansun Law; Toshiaki Maruyama; Jamie Lewis; Erick Giang; Alexander W Tarr; Zania Stamataki; Pablo Gastaminza; Francis V Chisari; Ian M Jones; Robert I Fox; Jonathan K Ball; Jane A McKeating; Norman M Kneteman; Dennis R Burton
Journal:  Nat Med       Date:  2007-12-06       Impact factor: 53.440

5.  Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection.

Authors:  Yoshiki Koizumi; Hirofumi Ohashi; Syo Nakajima; Yasuhito Tanaka; Takaji Wakita; Alan S Perelson; Shingo Iwami; Koichi Watashi
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-07       Impact factor: 11.205

6.  Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C.

Authors:  Fei Xiao; Isabel Fofana; Christine Thumann; Laurent Mailly; Roxane Alles; Eric Robinet; Nicolas Meyer; Mickaël Schaeffer; François Habersetzer; Michel Doffoël; Pieter Leyssen; Johan Neyts; Mirjam B Zeisel; Thomas F Baumert
Journal:  Gut       Date:  2014-05-21       Impact factor: 23.059

7.  Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody.

Authors:  Fei Xiao; Joachim Lupberger; Laurent Mailly; Garrick K Wilson; Philippe Aubert; François H T Duong; Diego Calabrese; Céline Leboeuf; Isabel Fofana; Christine Thumann; Simonetta Bandiera; Marc Lütgehetmann; Tassilo Volz; Christopher Davis; Helen J Harris; Christopher J Mee; Erika Girardi; Béatrice Chane-Woon-Ming; Maria Ericsson; Nicola Fletcher; Ralf Bartenschlager; Patrick Pessaux; Koen Vercauteren; Philip Meuleman; Pascal Villa; Lars Kaderali; Sébastien Pfeffer; Markus H Heim; Michel Neunlist; Mirjam B Zeisel; Maura Dandri; Jane A McKeating; Eric Robinet; Thomas F Baumert
Journal:  Nat Biotechnol       Date:  2015-03-23       Impact factor: 54.908

8.  Inhibitors of hepatitis C virus entry may be potent ingredients of optimal drug combinations.

Authors:  Pranesh Padmanabhan; Narendra M Dixit
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-16       Impact factor: 11.205

9.  Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs.

Authors:  Lin Shen; Susan Peterson; Ahmad R Sedaghat; Moira A McMahon; Marc Callender; Haili Zhang; Yan Zhou; Eleanor Pitt; Karen S Anderson; Edward P Acosta; Robert F Siliciano
Journal:  Nat Med       Date:  2008-06-15       Impact factor: 53.440

10.  Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees.

Authors:  Trevor J Morin; Teresa J Broering; Brett A Leav; Barbra M Blair; Kirk J Rowley; Elisabeth N Boucher; Yang Wang; Peter S Cheslock; Michael Knauber; David B Olsen; Steve W Ludmerer; Gyongyi Szabo; Robert W Finberg; Robert H Purcell; Robert E Lanford; Donna M Ambrosino; Deborah C Molrine; Gregory J Babcock
Journal:  PLoS Pathog       Date:  2012-08-30       Impact factor: 6.823
View more
  3 in total

Review 1.  Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era.

Authors:  Rubesh Raja; Subhasish Baral; Narendra M Dixit
Journal:  Immunol Rev       Date:  2018-09       Impact factor: 12.988

2.  Building a mechanistic mathematical model of hepatitis C virus entry.

Authors:  Mphatso Kalemera; Dilyana Mincheva; Joe Grove; Christopher J R Illingworth
Journal:  PLoS Comput Biol       Date:  2019-03-18       Impact factor: 4.475

3.  Modelling how responsiveness to interferon improves interferon-free treatment of hepatitis C virus infection.

Authors:  Vishnu Venugopal; Pranesh Padmanabhan; Rubesh Raja; Narendra M Dixit
Journal:  PLoS Comput Biol       Date:  2018-07-12       Impact factor: 4.475
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.